Comparison · NCT05732454-85b67d24
DB Period: Etrasimod 2 mg vs DB Period: Placebo: Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. DB Period: Etrasimod 2 mg vs DB Period: Placebo: Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities. Trial comparisons, record NCT05732454-85b67d24. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05732454-85b67d24
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.759 | 0.579 | 0.878 | wilson | |
| Risk in group 2 | 0.481 | 0.307 | 0.66 | wilson | |
| Risk difference, group 1 minus group 2 | 0.277 | 0.0237 | 0.488 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.58 | 1.01 | 2.45 | log | |
| Odds ratio, group 1 over group 2 | 3.38 | 1.09 | 10.6 | log | |
| Number needed to treat, for one more participant with the outcome on DB Period: Etrasimod 2 mg than on DB Period: Placebo | 3.61 | 2.05 | 42.1 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | DB Period: Etrasimod 2 mg | Participants who received etrasimod 2 mg orally once daily for 16 weeks in DB period of Part 1. | 22 | 29 | OG000 |
| Group 2 | DB Period: Placebo | Participants who received placebo matched to etrasimod orally once daily for 16 weeks in DB period of Part 1. | 13 | 27 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Part 1, DB Period: Number of Participants With Laboratory Test Abnormalities
- Description
- Laboratory assessments included hematology, clinical chemistry, urinalysis, other parameters and reflex tests. Number of participants with abnormalities in any of laboratory parameters is reported.
- Time frame
- DB Period: From first dose of study drug up to 16 Weeks of treatment
- Population
DB period: Safety analysis set included of all participants who were randomized and received at least 1 dose of study drug in DB period. Here, Overall Number of Participants Analyzed signifies number of participants evaluable for this outcome measure.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
- NCT number
- NCT05732454
- Phases
- PHASE2, PHASE3
- Conditions
- Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
- Interventions
- etrasimod, Placebo
- Lead sponsor
- Pfizer
- Results first posted
- 2025-05-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05732454?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05732454-85b67d24